GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
January 05 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in a virtual presentation at the
39th Annual J.P. Morgan Healthcare Conference on Tuesday, January
12, 2021, at 11:40 a.m. Eastern Time.
The presentation and Q&A session will be webcast live from
GBT’s website at www.gbt.com in the Investors section. A replay of
the webcast will be archived and available for one month following
the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical
company dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor), the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a P-selectin
inhibitor in development to address pain crises associated with the
disease, and GBT021601, the company’s next generation hemoglobin S
polymerization inhibitor. In addition, GBT’s drug discovery teams
are working on new targets to develop the next wave of treatments
for SCD. To learn more, please visit www.gbt.com and
follow the company on Twitter @GBT_news.
Contact Information:Steven Immergut (investors
and media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2024 to May 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2023 to May 2024